Provided by Tiger Trade Technology Pte. Ltd.

BioNTech SE

102.08
-9.3250-8.37%
Post-market: 102.500.4250+0.42%19:30 EDT
Volume:3.07M
Turnover:314.70M
Market Cap:25.64B
PE:-13.13
High:105.23
Open:102.34
Low:98.80
Close:111.40
52wk High:124.00
52wk Low:79.52
Shares:251.20M
Float Shares:108.00M
Volume Ratio:1.71
T/O Rate:2.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.7726
EPS(LYR):-5.5184
ROE:-9.30%
ROA:-5.41%
PB:1.26
PE(LYR):-18.50

Loading ...

BioNTech SE Slides as Bold HIV Bet Takes Shape

TIPRANKS
·
Aug 29

BioNTech SE ADR Falls 8.4%, Underperforms Market

Dow Jones
·
Aug 29

Biontech SE Stock (BNTX) Closed Down by 8.37% on Aug 28: What Signal Does It Send?

TradingKey
·
Aug 29

BioNTech Stock Falls on Cancer Vaccine Setback Days After Moderna's Big Win

Dow Jones
·
Aug 29

BioNTech on Track for Worst Day Since March After Ending Colorectal Cancer Trial

Reuters
·
Aug 29

BioNTech Stock (BNTX) Is Tumbling on Friday – Here’s Why

TIPRANKS
·
Aug 29

Cevumeran trial termination a ‘clear setback’ for BioNTech, says BMO Capital

TIPRANKS
·
Aug 29

U.S. Stocks on the MOVE-Halliburton, BioNTech, Kazia Therapeutics

Reuters
·
Aug 29

Top Midday Stories: Warsh Says Inflation Data 'Concerning'; Advent, Stripe Drop $50 Billion Bid to Buy PayPal

MT Newswires Live
·
Aug 28

European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading

MT Newswires Live
·
Aug 28

mRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley

TIPRANKS
·
Aug 28

Market Movers | GAP Jumps 18%; Affirm Jumps 14%; IREN Stock Drops 7%; Rubrik Falls 6%; BioNTech Falls 9%

Tiger Newspress
·
Aug 28

BioNTech Halts Phase 2 mRNA Monotherapy Trial in Resected Colorectal Cancer After DSMB Review

TIPRANKS
·
Aug 28

Movement Alert|BioNTech SE Falls 8.22% in Regular Trading, Terminates Phase 2 Cancer Immunotherapy Trial While COVID Vaccine Approval Narrows

Market Focus
·
Aug 28

BioNTech Terminates Phase 2 Trial of Autogene Cevumeran in Colorectal Cancer

MT Newswires Live
·
Aug 28

BioNTech to Terminate Mid-Stage Trial of MRNA Cancer Vaccine

Reuters
·
Aug 28

Movement Alert|BioNTech SE Falls 11.62% in Pre-Market Trading, COVID-19 Vaccine Approved but Eligible Population Sharply Narrowed

Market Focus
·
Aug 28

FDA Approves Seasonal Covid-19 Vaccines from Moderna, Pfizer, BioNTech

Dow Jones
·
Aug 28

Pfizer and BioNTech receive FDA approval for XFG-adapted COVID-19 vaccine

TIPRANKS
·
Aug 28

Pfizer, BioNTech Win FDA Approval for XFG-Adapted COVID-19 Vaccine in High-Risk US Adults

Reuters
·
Aug 28